title: Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
abstract: Pralatrexate is a folate analogue metabolic inhibitor manufactured by Allos Therapeutics, Inc., a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. In both preclinical and clinical studies, pralatrexate demonstrated activity in lymphoma. Pralatrexate was US FDA approved for the treatment of relapsed/refractory peripheral T-cell lymphoma in 2009. Approval was based on data from the PROPEL trial that demonstrated an overall response rate of 29% in a heavily pretreated patient population. The dose and schedule of pralatrexate is 30-mg/m(2) weekly for 6 weeks, given in 7-week cycles. Folate and vitamin B12 supplementation are required to minimize toxicity. The most common toxicities are mucositis, thrombocytopenia, nausea and fatigue.
authors.affiliation: Department of Internal Medicine (Hematology), Yale University School of Medicine, 333 Cedar Street, PO Box 208032, New Haven, CT 06520, USA.
authors.forename: Terri
authors.initials: T
authors.lastname: Parker
authors.forename: Lisa
authors.initials: L
authors.lastname: Barbarotta
authors.forename: Francine
authors.initials: F
authors.lastname: Foss
mesh_terms: D000630:Aminopterin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D012008:Recurrence
chemical_list: C418863:10-propargyl-10-deazaaminopterin; D000970:Antineoplastic Agents; D000630:Aminopterin